Multiple Myeloma VA Rating

Overview

Multiple myeloma is a plasma cell cancer affecting bone marrow. MGUS (monoclonal gammopathy of undetermined significance) is the precursor and is also presumptive.

Long-term residuals include bone disease, anemia, kidney impairment, and recurrent infection.

In Depth

Multiple myeloma is a malignancy of plasma cells in the bone marrow. It appears on the Agent Orange presumptive list at 38 CFR § 3.309(e), and the PACT Act added multi-myeloma of any type to the presumptive list for veterans with qualifying toxic-exposure service, including burn-pit and Gulf War-era service in the covered locations. Where presumptive service connection applies, the veteran does not need a medical nexus opinion linking the disease to service — the qualifying service plus the diagnosis is the pathway.

The evaluation itself follows 38 CFR § 4.117, Diagnostic Code 7712. Active disease and the active treatment phase are evaluated at 100 percent. Malignancies rated at 100 percent under 38 CFR Part 4 carry a note directing that the total evaluation continues during active disease and for six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. VA must then schedule a mandatory examination, and any reduction from the 100 percent evaluation is made under the procedures in 38 CFR § 3.105(e) — advance written notice, at least 60 days to submit evidence, and 30 days to request a predetermination hearing. If the mandatory exam did not happen, or the notice period was not honored, that is a procedural issue separate from the medical question of how bad the residuals are.

After the convalescent period, the evaluation is built from residuals, each rated under the diagnostic code for the affected body system and combined under 38 CFR § 4.25. Common residuals that go unrated because no one claimed them include chemotherapy-induced peripheral neuropathy, fatigue, cognitive complaints, hypothyroidism after radiation to the neck, voiding dysfunction, erectile dysfunction with special monthly compensation for loss of use of a creative organ under 38 CFR § 3.350(a), surgical scars, and mental health conditions secondary to the diagnosis and treatment. In myeloma specifically, the residuals most often supported by the treatment record are anemia and other cytopenias, renal impairment from light-chain deposition, lytic bone disease and pathologic fractures, recurrent infection from immunoparesis, and chemotherapy-induced peripheral neuropathy — bortezomib and thalidomide-class agents are well known for it.

Maintenance therapy is a recurring point of dispute. Many patients remain on lenalidomide or a similar agent indefinitely after transplant or induction. Whether that constitutes continuing therapeutic treatment for purposes of the six-month note is a fact question, and the oncology record — not the veteran's summary of it — is what answers it.

MGUS and smoldering myeloma are precursor states. They can be service connected where the presumptive criteria are met, but an asymptomatic precursor with no functional impairment is often evaluated at zero percent. A zero percent evaluation still matters: it establishes service connection, which means a later progression to active myeloma is an increase on an established condition rather than a new claim.

How to Establish Service Connection

• Presumptive: Agent Orange (§ 3.309(e)) and PACT Act.
• Direct: documented exposure.

Rating Criteria

Paraphrased from 38 CFR § 4.117, DC 7712

See what each percentage pays in 2026 and how it combines with your current rating →

Evidence Checklist

• Bone marrow biopsy.
• Serum and urine protein electrophoresis.
• Skeletal survey.
• Exposure documentation.

Evidence VA Commonly Cites in These Claims

Descriptive summary of evidence types frequently referenced in rating decisions for this condition. Not a checklist of actions to take — every claim is decided on its own facts.

• ★Get the pathology report and the oncology treatment summary into the file — the dates therapy started and stopped are what set the six-month convalescent window.
• ★List every residual separately when the issue is evaluated after treatment; residuals that are never identified are generally never rated.
• ★Ask the treating oncologist to document ongoing surveillance, maintenance therapy, or hormone therapy where it applies — continuing therapy can be relevant to whether the active-disease evaluation should have continued.
• ★For presumptive exposure, put the service documentation in the file: DD-214, unit assignments, deployment orders, or the location and date range establishing covered service.
• ★Where a reduction from 100 percent is proposed, respond within the 60-day evidence window and request the predetermination hearing within 30 days if you want one — those windows are separate.
• ★Get the bone marrow biopsy report, the serum and urine protein electrophoresis with free light chain ratio, and the skeletal survey or whole-body imaging into the record — these establish both diagnosis and organ involvement.
• ★Have the oncology record state plainly whether the veteran is on maintenance therapy and what the intent of that therapy is.
• ★Document renal function separately; CKD from myeloma is rated under the genitourinary criteria and frequently drives a substantial part of the combined evaluation.

Illustrative Scenarios

These are hypothetical educational examples — not actual case results, predictions, or guarantees of outcomes.

Common pitfalls VA sees

• Assuming the 100 percent evaluation continues indefinitely. It does not; the schedule contemplates reevaluation six months after therapy ends.
• Letting the mandatory post-treatment examination pass without documenting residuals, then disagreeing only after the reduction takes effect.
• Claiming only the cancer and never claiming the neuropathy, scars, fatigue, endocrine, or mental health residuals it produced.
• Missing the 60-day evidence window in a proposed-reduction letter because it looks like a form letter rather than a deadline.

Common Secondary Conditions

Conditions frequently service-connected as secondary to Multiple Myeloma:

What the C&P Exam Documents

General information about how this condition is typically evaluated. This is not coaching on what to say and is not a substitute for medical or legal advice.

• →Bring the oncology treatment summary listing regimen names and start/stop dates.
• →Describe neuropathy by function — buttons, stairs, driving, burning at night — not just 'numbness.'
• →Report infection frequency and hospitalizations over the past year; recurrent infection is part of the hematologic picture.
• →Mention bone pain, height loss, and any fracture history; lytic disease is rated on its own effects.

Frequently Asked Questions